On the other hand, mutant IDH obtains a neomorphic activity that converts a-KG to d-2-hydroxyglutarate (d-2-HG) in an NADPH-consuming reduction, which competitively inhibits a-KG-dependent dioxygenases, eventually shifting the genome-wide histone and DNA methylome in gliomas [32,33]. This evidence concerns the gene IDH2 and central nervous system cancer.